# South Korea Medical Morphine Market

> South Korea Medical Morphine Market Research Report By Route of Administration (Oral, Injectables), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Others), By Application (Myocardial Infarction, Diarrhea, Arthritis, Kidney Stones, Cancer, Others) and By End User (Hospitals and Clinics, Ambulatory Surgical Centers, Home Care) -Forecast to 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 7.34%
- **2024:** $ 619.1 Million
- **2025:** $ 664.54 Million
- **2035:** $ 1,350 Million
- **Key Players:** Purdue Pharma (US), Mallinckrodt Pharmaceuticals (US), Teva Pharmaceutical Industries (IL), Mundipharma (GB), Hikma Pharmaceuticals (GB), Amgen (US), Sandoz (CH), Boehringer Ingelheim (DE)

**Report ID:** MRFR/MED/54269-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** February 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/south-korea-medical-morphine-market-56035

---

## Market Summary

## **South Korea Medical Morphine Market Overview**

As per MRFR analysis, the South Korea Medical Morphine Market Size was estimated at 577.42 (USD Million) in 2023. The South Korea Medical Morphine Market Industry is expected to grow from 619(USD Million) in 2024 to 1,327 (USD Million) by 2035. The South Korea Medical Morphine Market CAGR (growth rate) is expected to be around 7.178% during the forecast period (2025 - 2035).

**Key South Korea Medical Morphine Market Trends Highlighted**

The South Korea Medical Morphine Market is experiencing several significant trends that reflect its evolving landscape. One key market driver is the increasing prevalence of chronic pain conditions as the population ages, necessitating effective pain management solutions. South Korea's government is also focused on enhancing palliative care support, which further drives demand for morphine as an essential component in pain relief protocols. Recent legislative initiatives aim to streamline regulations surrounding opioid prescribing, allowing medical professionals to have better access to morphine for patients in need.

Opportunities to be captured include the potential for greater education around the safe use of opioids, helping to mitigate stigma, and addressing concerns about misuse.

Healthcare providers and pharmaceutical companies can work together on marketing campaigns to promote the value of morphine in relieving severe pain within terminal cases, possibly contributing to a more conservative and responsible approach toward opioid use. In addition, there is a further shift towards custom-tailored pain relief, where medical practitioners seek to adjust their approach to fit specific patients.

This could increase the willingness to accept morphine within the wider framework of treatment, thus strengthening the market. Furthermore, new research is being done on the formulation and delivery of drugs to morphine, which aims at improving patient outcomes and better compliance through the modification of its administration.

As these trends unfold, the South Korea Medical Morphine Market is poised for continued growth, reflecting a combination of regulatory support, demographic changes, and a growing recognition of the importance of effective pain management in healthcare.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**South Korea Medical Morphine Market Drivers**

**Increasing Prevalence of Chronic Pain Conditions**

The South Korea Medical Morphine Market Industry is witnessing significant growth due to the rising incidence of chronic pain conditions among the population. According to the Korean National Health Insurance Service, more than 20% of the South Korean adult population suffers from chronic pain, translating to over 10 million individuals.

This alarming statistic suggests a growing need for effective pain management solutions, including morphine. The National Institute for Health and Care Excellence (NICE) advocates the use of strong opioids, such as morphine, for patients with severe or refractory pain, correlating with the rise in demand.Moreover, initiatives taken by the Korean Ministry of Health and Welfare to improve pain management protocols further bolster the necessity for medical morphine, securing its role as a critical component in therapeutic strategies.

**Aging Population**

South Korea's demographic landscape is evolving rapidly, with a notable increase in the aging population. As per Statistics Korea, it is projected that by 2025, approximately 18% of South Koreans will be aged 65 and above. Older adults commonly experience more severe pain due to conditions like arthritis, cancer, and other age-related ailments, thereby increasing the demand for effective pain management solutions, including medical morphine.

This demographic shift raises the profile of the South Korea Medical Morphine Market Industry as healthcare providers aim to cater to the unique needs of elderly patients.Additionally, the Korean Geriatric Society highlights the importance of adequate pain management in enhancing the quality of life for seniors, further propelling market growth.

**Government Initiatives and Policies**

The South Korean government has implemented a series of initiatives aimed at addressing the challenges associated with pain management. Recently, the Ministry of Health and Welfare launched a national program to improve access to palliative care and pain relief medications, which include medical morphine. This initiative seeks to provide better support for patients suffering from chronic and terminal illnesses.

With the growing discussion on the opioid crisis, the government is balancing the need for pain management against potential misuse, thus focusing on tighter regulations and responsible prescribing practices.

The Korean Physicians Association has also been advocating for better education on opioid prescribing, which is likely to increase the comfort level of healthcare providers in prescribing morphine, thereby boosting market growth within the South Korea Medical Morphine Market Industry.

**Advancements in Pain Management Research**

Research and Development (R&D) within the field of pain management continues to evolve, presenting new opportunities for the South Korea Medical Morphine Market Industry. Academic institutions, such as Seoul National University, are actively engaging in research to explore advanced methodologies concerning pain relief and opioid formulations.

Findings from these studies indicate innovative ways to enhance the efficacy and safety of morphine usage while minimizing the risk of addiction.For instance, the integration of controlled-release delivery systems is showing promise in reducing the frequency of doses, thereby improving patient adherence.

The increased investment in R&D by both government and private sectors has the potential to drive significant advancements in treatment options, fostering a robust growth trajectory for the medical morphine market.

**South Korea Medical Morphine Market Segment Insights**

**Medical Morphine Market Route of Administration Insights**

The Route of Administration segment within the South Korea Medical Morphine Market is critical in determining how patients receive effective pain relief. This segment is primarily divided into Oral and Injectables categories, both of which play significant roles in patient care and treatment protocols. The Oral route is often preferred for its convenience and ease of use, as it allows patients to manage their pain without the need for medical supervision.

It is particularly beneficial for chronic pain management, where long-term therapy is required, thus making it a popular option among physicians. On the other hand, Injectables serve as an essential alternative for acute pain management, especially in surgical settings or in cases where immediate relief is necessary. This method allows for rapid absorption and is crucial in controlled hospital environments.

As South Korea continues to innovate in its healthcare sector, the demand for these routes of administration is expected to rise, influenced by increased awareness of pain management and evolving patient needs. Furthermore, the aging population in South Korea is a contributing factor, as elderly individuals often require effective pain management solutions.

Trends towards personalized medicine and tailor-made treatment solutions further contribute to the growth of the injectables market, as healthcare providers seek to maximize efficacy through targeted delivery methods. The South Korea Medical Morphine Market statistics also indicate that regulatory frameworks and improved access to healthcare facilities play significant roles in shaping the utilization of these routes.

Notably, government initiatives that aim to improve opioid prescription practices while addressing safety concerns are pivotal for the evolution of both Oral and Injectable morphine administration methods. Overall, the Route of Administration segment represents a crucial aspect of the South Korea Medical Morphine Market, reflecting the broader trends in pain management strategies and healthcare advancements in the region.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Medical Morphine Market Distribution Channel Insights**

The Distribution Channel segment of the South Korea Medical Morphine Market plays a crucial role in ensuring the availability of this essential medication, with various channels contributing to the market dynamics. Hospital pharmacies are significant as they provide direct access to morphine for inpatients, particularly those undergoing surgeries or managing chronic pain.

Online pharmacies have gained traction, driven by the growing shift toward digital healthcare solutions, offering greater convenience to patients who prefer ordering medications from home.Retail pharmacies continue to dominate the market, serving as the primary point for consumers to obtain prescriptions and over-the-counter medications, ensuring that morphine is accessible for widespread use. Additionally, other distribution methods cater to specialized needs or niche markets, enhancing the overall reach of medical morphine.

The rise in chronic pain conditions and serious illnesses in South Korea is fueling the demand for morphine, prompting further development in these distribution channels. Overall, the diverse nature of the distribution channels reflects the complexities of the South Korea Medical Morphine Market, facilitating effective access to this critical pharmaceutical product.

**Medical Morphine Market Application Insights**

The South Korea Medical Morphine Market focused on the Application segment includes critical areas such as Myocardial Infarction, Diarrhea, Arthritis, Kidney Stones, Cancer, and Others. Within this diverse landscape, Cancer treatment emerges as a significant driver due to the increasing prevalence of this disease in South Korea. Morphine is essential for managing pain effectively and enhancing the quality of life for patients undergoing cancer therapies.

Myocardial Infarction and Arthritis also represent crucial applications, as they demand immediate intervention for pain relief, thus maintaining a steady demand for medical morphine.Additionally, morbidities like Diarrhea and Kidney Stones necessitate effective pain management solutions, further contributing to the growing utilization of morphine in healthcare settings.

The importance of these applications in the overall South Korea Medical Morphine Market statistics cannot be overstated, as they respond to pressing health challenges faced by the population. Furthermore, evolving healthcare policies and increasing awareness surrounding chronic conditions serve as a backdrop, offering opportunities for growth and innovation within the market.

**Medical Morphine Market End User Insights**

The South Korea Medical Morphine Market has seen a notable segmentation in its End User category, which primarily includes Hospitals and Clinics, Ambulatory Surgical Centers, and Home Care settings, each playing a crucial role in patient care and pain management. Hospitals and Clinics are the dominant settings where medical morphine is prescribed, owing to their advanced infrastructure and access to specialized professionals.

Ambulatory Surgical Centers are gaining importance due to their increasing focus on outpatient services, providing efficient access to pain relief therapies for procedures without requiring long hospitalization.Home Care is also emerging as a significant segment, driven by the growing preference for in-home treatments and an aging population requiring ongoing pain management solutions.

This shift not only helps in reducing hospital stays but also caters to personalized patient care. The combined dynamics of these End User segments reflect a comprehensive strategy towards improving pain management in South Korea, aligning with government efforts to enhance healthcare accessibility and quality. Additionally, rising awareness of chronic pain conditions among healthcare providers further contributes to the robust demand for medical morphine across these critical sectors.

**South Korea Medical Morphine Market Key Players and Competitive Insights**

The South Korea Medical Morphine Market is characterized by a dynamic competitive landscape shaped by several manufacturers and stakeholders aiming to cater to the growing demand for pain management solutions. As this market continues to develop, companies must navigate regulatory environments, increasing scrutiny on opioid prescriptions, and the emergence of alternative therapies.

The competitive insights reveal a landscape where innovation and quality assurance are vital components for success as firms strive to expand their market share and reinforce their reputations in the healthcare sector.

Understanding the strategies employed by various players, including product differentiation, pricing strategies, and compliance with stringent regulations, is essential in identifying key opportunities and challenges within this market.ChanMed has positioned itself as a formidable contender within the South Korea Medical Morphine Market, leveraging its strengths to enhance its presence.

The company focuses on maintaining high-quality standards in its product offerings, ensuring that its morphine formulations meet the rigorous safety and efficacy criteria required in the medical field.

ChanMed has established relationships with healthcare providers, which bolsters its distribution capabilities and supports its efforts in responding to the needs of patients suffering from severe pain. Moreover, the firm invests in research and development, aiming to introduce innovative solutions that address specific therapeutic issues.

By understanding the unique needs of the South Korean market and adapting swiftly to changing regulations and consumer preferences, ChanMed maintains a competitive edge in this evolving landscape.Medytox operates within the South Korea Medical Morphine Market with a strategic approach to product development and market penetration.

The company offers a range of morphine-based products aimed at addressing various pain management needs in clinical settings. Medytox's robust market presence stems from its significant investment in research and innovation, producing high-quality products that adhere to strict regulatory standards.

The company has formed key partnerships and collaborations within the healthcare industry, enhancing its ability to distribute effectively. Medytox has also explored opportunities for mergers and acquisitions to strengthen its product pipeline and expand its footprint in the market.

By focusing on continuous improvement and adaptability, Medytox is well-positioned to respond to the needs of healthcare providers and patients in South Korea, thus reinforcing its stature in the competitive medical morphine arena.

**Key Companies in the South Korea Medical Morphine Market Include**

- ChanMed
- Medytox
- Korea Vaccine
- Hanmi Pharmaceutical
- Samyang Biopharmaceuticals
- DongA ST
- Boryung Pharmaceutical
- JW Pharmaceutical
- Daewoong Pharmaceutical
- Korean Drug
- Triple A Pharma
- Green Cross
- Yuhan Corporation
- Hana Pharm
- Korea United Pharm

**South Korea Medical Morphine Market Industry Developments**

The South Korea Medical Morphine Market has seen significant activity in recent months, driven by increasing demand for pain management solutions amid the ongoing challenges of the healthcare sector. Notable advancements by companies such as Hanmi Pharmaceutical and Yuhan Corporation have contributed to the development of innovative morphine-based formulations.

The market has also been influenced by the rise in regulatory approvals aimed at enhancing accessibility to essential opioid medications. In terms of mergers and acquisitions, Daewoong Pharmaceutical announced the acquisition of a small biotech firm in September 2023 to bolster its analgesic portfolio, reinforcing its position in the morphine market.

Growth potential is evident as the market valuation for companies like JW Pharmaceutical and Boryung Pharmaceutical continues to rise, reflecting an uptrend in both production capabilities and market share.

Additionally, there have been fluctuations in raw material sourcing as the government takes steps to stabilize supply chains. Over the last two years, from 2021 to 2023, there has been a concerted push by the South Korean authorities to ensure the sustainable supply of morphine and related products, driven by the increasing focus on chronic pain management nationwide.

**South Korea Medical Morphine Market Segmentation Insights**

**Medical Morphine Market Route of Administration****Outlook**

- Oral
- Injectables

**Medical Morphine Market Distribution Channel****Outlook**

- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
- Others

**Medical Morphine Market Application****Outlook**

- Myocardial Infarction
- Diarrhea
- Arthritis
- Kidney Stones
- Cancer
- Others

**Medical Morphine Market End User****Outlook**

- Hospitals and Clinics
- Ambulatory Surgical Centers
- Home Care

## Market Drivers

### Enhanced Regulatory Frameworks

The medical morphine market is positively influenced by the establishment of enhanced regulatory frameworks in South Korea. The government has implemented policies aimed at ensuring the safe and effective use of opioids, including morphine, for pain management. These regulations are designed to balance the need for pain relief with the risks of addiction and misuse. As a result, healthcare professionals are more confident in prescribing morphine, knowing that there are guidelines in place to monitor its use. This regulatory support is crucial for the medical morphine market, as it fosters a more favorable environment for both manufacturers and healthcare providers. The market is expected to grow as these frameworks continue to evolve, promoting responsible prescribing practices.

### Increasing Pain Management Needs

The medical morphine market in South Korea is experiencing growth due to the rising demand for effective pain management solutions. As the population ages, the prevalence of chronic pain conditions, such as arthritis and cancer, is increasing. This demographic shift necessitates the use of potent analgesics like morphine. According to recent data, approximately 30% of the elderly population in South Korea suffers from chronic pain, which drives the need for medical morphine. Furthermore, healthcare providers are increasingly recognizing the importance of addressing pain as a critical component of patient care, thereby enhancing the market's potential. The medical morphine market is likely to benefit from this growing awareness and the subsequent increase in prescriptions for opioid medications.

### Growing Focus on Cancer Treatment

The medical morphine market is significantly influenced by the increasing focus on cancer treatment in South Korea. As cancer rates rise, the need for effective pain management strategies becomes more critical. Morphine is widely recognized as a first-line treatment for cancer-related pain, and its use is expected to grow as more patients seek relief from debilitating symptoms. Recent statistics indicate that cancer is the leading cause of death in South Korea, with over 200,000 new cases diagnosed annually. This alarming trend underscores the necessity for effective pain management solutions, positioning the medical morphine market for substantial growth. As healthcare providers prioritize pain relief in cancer care, the demand for morphine is likely to escalate.

### Rising Awareness of Palliative Care

There is a growing recognition of the importance of palliative care in South Korea, which significantly impacts the medical morphine market. Palliative care focuses on providing relief from the symptoms and stress of serious illnesses, and morphine is a key component in managing pain for patients in such settings. As healthcare providers and families become more aware of the benefits of palliative care, the demand for morphine is likely to increase. Recent studies indicate that nearly 40% of patients receiving palliative care report significant pain relief when treated with opioids. This trend suggests that the medical morphine market will continue to expand as more healthcare facilities adopt palliative care practices, ultimately improving the quality of life for patients.

### Technological Advancements in Drug Delivery

Innovations in drug delivery systems are transforming the medical morphine market in South Korea. New technologies, such as transdermal patches and extended-release formulations, are enhancing the efficacy and safety of morphine administration. These advancements allow for more precise dosing and reduced side effects, making morphine a more attractive option for pain management. The medical morphine market is likely to see increased adoption of these technologies, as they address some of the concerns associated with traditional opioid use. Furthermore, the integration of digital health solutions, such as mobile apps for monitoring pain levels, may further support the effective use of morphine in clinical settings, potentially leading to a more favorable market landscape.

## Future Outlook

The [Medical Morphine Market](https://www.marketresearchfuture.com/reports/medical-morphine-market-6084) in South Korea is projected to grow at a 7.34% CAGR from 2025 to 2035, driven by increasing pain management needs and regulatory support.

**New opportunities:**

- Development of telehealth platforms for prescription management
- Investment in advanced drug delivery systems
- Expansion of partnerships with pain management clinics

By 2035, the market is expected to achieve robust growth and enhanced accessibility.

## Segment Insights

### By Route of Administration: Oral (Largest) vs. Injectables (Fastest-Growing)

In the South Korea medical morphine market, the route of administration is characterized by significant preference for Oral forms, which hold the largest market share. Injectables, while less consumed currently, are rapidly acquiring attention and exhibit strong adoption trends. This distribution reflects the varied use cases and patient preferences in the region, where Oral morphine remains a go-to option for many healthcare providers and patients due to its ease of administration.

Looking ahead, growth trends in this segment are driven by increasing demand for pain management solutions and a growing patient population requiring chronic pain treatment. While Oral morphine remains dominant due to established ease of use, the Injectables segment is expected to witness the fastest growth as advancements in delivery methods and healthcare provider recommendations encourage more usage. The market dynamics suggest a robust pipeline for further innovations in both segments.

Oral (Dominant) vs. Injectables (Emerging)

The Oral segment of the South Korea medical morphine market is characterized by broad acceptance and a strong historical foundation, making it the dominant route for administration. Patients favor Oral morphine due to its convenience and the familiarity of oral dosage forms. On the other hand, the Injectables segment is viewed as emerging, capturing significant interest among healthcare professionals seeking more immediate effects in pain management. This segment appeals particularly in hospital settings, where rapid patient response to analgesics is critical. Growing familiarity with injectable technologies and potential therapeutic advantages are poised to enhance market penetration for injectables, thereby shifting dynamics within this segment. Both routes cater to specific patient profiles and treatment goals, ensuring their coexistence in the healthcare landscape.

### By Distribution Channel: Hospital Pharmacy (Largest) vs. Online Pharmacy (Fastest-Growing)

In the South Korea medical morphine market, the distribution channel landscape is significantly shaped by various pharmacy types. Hospital pharmacies command the largest market share, primarily due to their critical role in pain management and controlled substance dispensing for in-patient care. Meanwhile, retail pharmacies and online pharmacies occupy a smaller but vital share, addressing outpatient needs with varying convenience levels. Online pharmacies are beginning to capture attention, especially with increasing digitalization in healthcare.

Growth trends within the distribution channels are particularly compelling. Online pharmacies are considered the fastest-growing segment, fueled by a heightened demand for convenient access to medications and the expansion of e-commerce in healthcare. Factors such as the aging population and increasing chronic pain cases contribute to the robust growth of hospital pharmacies, emphasizing the importance of accessibility in pain management strategies.

Hospital Pharmacy (Dominant) vs. Online Pharmacy (Emerging)

Hospital pharmacies play a dominant role in the South Korea medical morphine market by providing essential medications within healthcare facilities. They cater to in-patient needs, ensuring the safe and controlled distribution of morphine for pain relief. These pharmacies prioritize stringent regulatory compliance and inventory management, offering a consistent and reliable supply of morphine. On the other hand, online pharmacies are emerging as a significant player, driven by the digital transformation of the healthcare sector. They offer the convenience of home delivery and accessibility for patients managing chronic conditions, thereby expanding the market reach of medical morphine in the outpatient segment. This duality represents a crucial dynamic, with established hospital pharmacies coexisting alongside innovative online platforms.

### By Application: Cancer (Largest) vs. Myocardial Infarction (Fastest-Growing)

In the South Korea medical morphine market, the application segment is marked by diverse uses, with cancer treatment holding the largest share due to its critical role in pain management for patients. The following in significance are myocardial infarction and arthritis, which finish closely behind, emphasizing the multi-faceted nature of morphine applications in alleviating severe pain across various medical conditions.

Recent trends indicate a significant shift towards the management of chronic conditions, resulting in an increased demand for morphine in indications such as kidney stones and diarrhea. Additionally, there is a growing recognition of the necessity for effective pain relief in post-operative care, boosting the application of morphine, particularly in cancer management as treatment regimens become more aggressive.

Cancer (Dominant) vs. Diarrhea (Emerging)

Cancer remains the dominant application for morphine usage, driven by the increasing incidence of cancer cases in South Korea and a rising awareness of palliative care principles. Its characteristics are rooted in addressing severe pain for terminal patients, ensuring comfort during the late stages of the disease. Meanwhile, diarrhea is emerging as an important application due to a growing focus on managing associated pain from chronic conditions that lead to this symptom. As medical professionals increasingly recognize the role of morphine in improving patient quality of life in various diagnoses, both applications are set to drive significant changes in prescribing practices.

### By End User: Hospitals and Clinics (Largest) vs. Home Care (Fastest-Growing)

In the South Korea medical morphine market, the distribution of market share among end users reveals that hospitals and clinics hold a significant portion due to their integral role in pain management and palliative care. These establishments benefit from established protocols and infrastructure, allowing them to administer morphine effectively. Ambulatory surgical centers also play a role, albeit smaller, focusing on outpatient procedures which require efficient pain management solutions. Home care has seen an increased focus lately, responding to growing demand for at-home treatment options.

The growth trends within this segment are influenced by several factors, including the rising aging population that necessitates chronic pain management and the ongoing advancements in medical practices. Hospitals and clinics continue to prioritize patient-centered care, driving morphine usage, while home care's growth is accelerated by innovations in telehealth and patient monitoring systems. The shift towards more personalized care is likely to increase the prevalence of morphine prescriptions across these settings.

Hospitals and Clinics (Dominant) vs. Home Care (Emerging)

Hospitals and clinics represent the dominant end user in the South Korea medical morphine market, benefiting from their structural capabilities to manage complex pain scenarios through established protocols. Their ability to provide comprehensive care, integrated with a multidisciplinary approach, ensures effective morphine administration for various patient needs. Conversely, home care, although an emerging facet, is rapidly gaining traction, driven by patient preference for at-home care and advances in medical technology that facilitate safety and effectiveness. This segment caters primarily to patients with chronic conditions or those recovering from surgery, demonstrating a shift towards personalized care. The synergy of improved medical practices and home health technologies highlights the growing importance of home care in the overall morphine landscape.

## Competitive Benchmarking

The medical morphine market in South Korea is characterized by a competitive landscape that is increasingly shaped by innovation, regulatory compliance, and strategic partnerships. Key players such as Purdue Pharma (US), Teva Pharmaceutical Industries (IL), and Hikma Pharmaceuticals (GB) are actively engaged in enhancing their market presence through various strategic initiatives. Purdue Pharma (US) has focused on developing advanced formulations of morphine that aim to mitigate abuse potential, thereby aligning with regulatory trends favoring safer opioid options. Meanwhile, Teva Pharmaceutical Industries (IL) has been expanding its product portfolio through strategic acquisitions, which enhances its competitive positioning in the market. Hikma Pharmaceuticals (GB) appears to be concentrating on regional expansion, particularly in Asia, to capitalize on the growing demand for pain management solutions, thus shaping the competitive dynamics of the market.
In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and improve supply chain efficiency. This approach not only enhances responsiveness to market demands but also aligns with the broader trend of optimizing supply chains in the pharmaceutical sector. The market structure is moderately fragmented, with several players vying for market share, yet the collective influence of major companies is significant in driving innovation and setting industry standards.
In October 2025, Purdue Pharma (US) announced a partnership with a local South Korean biotech firm to co-develop a new morphine delivery system that utilizes nanotechnology. This strategic move is likely to enhance Purdue's product offerings and address the growing demand for more effective pain management solutions. The collaboration may also facilitate faster regulatory approvals, given the local expertise of the partner firm.
In September 2025, Teva Pharmaceutical Industries (IL) launched a new line of extended-release morphine formulations specifically designed for the Asian market. This initiative not only reflects Teva's commitment to addressing regional needs but also positions the company to capture a larger share of the market by offering tailored solutions. The launch is expected to strengthen Teva's competitive edge in a landscape that increasingly values customized healthcare solutions.
In August 2025, Hikma Pharmaceuticals (GB) expanded its manufacturing capabilities in South Korea by investing in a new facility aimed at increasing production capacity for morphine products. This investment underscores Hikma's strategy to enhance supply chain reliability and meet the rising demand for pain management therapies in the region. The facility is anticipated to improve operational efficiency and reduce lead times, thereby solidifying Hikma's market position.
As of November 2025, the competitive trends in the medical morphine market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in drug development and distribution. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in navigating regulatory complexities and enhancing innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological advancements, innovative product offerings, and robust supply chain management. This shift indicates a broader industry trend towards prioritizing quality and reliability over cost, which may redefine market dynamics in the coming years.

## Recent News & Developments

The South Korea Medical Morphine Market has seen significant activity in recent months, driven by increasing demand for pain management solutions amid the ongoing challenges of the healthcare sector. Notable advancements by companies such as Hanmi Pharmaceutical and Yuhan Corporation have contributed to the development of innovative morphine-based formulations.

The market has also been influenced by the rise in regulatory approvals aimed at enhancing accessibility to essential opioid medications. In terms of mergers and acquisitions, Daewoong Pharmaceutical announced the acquisition of a small biotech firm in September 2023 to bolster its analgesic portfolio, reinforcing its position in the morphine market.

Growth potential is evident as the market valuation for companies like JW Pharmaceutical and Boryung Pharmaceutical continues to rise, reflecting an uptrend in both production capabilities and market share.

Additionally, there have been fluctuations in raw material sourcing as the government takes steps to stabilize supply chains. Over the last two years, from 2021 to 2023, there has been a concerted push by the South Korean authorities to ensure the sustainable supply of morphine and related products, driven by the increasing focus on chronic pain management nationwide.

## Report Scope

| MARKET SIZE 2024 | 619.1(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 664.54(USD Million) |
| MARKET SIZE 2035 | 1350.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.34% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Purdue Pharma (US), Mallinckrodt Pharmaceuticals (US), Teva Pharmaceutical Industries (IL), Mundipharma (GB), Hikma Pharmaceuticals (GB), Amgen (US), Sandoz (CH), Boehringer Ingelheim (DE) |
| Segments Covered | Route of Administration, Distribution Channel, Application, End User |
| Key Market Opportunities | Emerging pain management technologies enhance growth potential in the medical morphine market. |
| Key Market Dynamics | Regulatory changes and competitive pressures shape the evolving landscape of the medical morphine market in South Korea. |
| Countries Covered | South Korea |

## Frequently Asked Questions

**Q: What was the market valuation of the medical morphine market in 2024?**
A: The market valuation was $619.1 Million in 2024.

**Q: What is the projected market valuation for the medical morphine market by 2035?**
A: The projected valuation for 2035 is $1350.0 Million.

**Q: What is the expected CAGR for the medical morphine market during the forecast period 2025 - 2035?**
A: The expected CAGR during the forecast period 2025 - 2035 is 7.34%.

**Q: Which companies are the key players in the medical morphine market?**
A: Key players include Purdue Pharma, Mallinckrodt Pharmaceuticals, Teva Pharmaceutical Industries, Mundipharma, Hikma Pharmaceuticals, Amgen, Sandoz, and Boehringer Ingelheim.

**Q: What are the main routes of administration for medical morphine?**
A: The main routes of administration are oral and injectables, with oral valued at $309.55 Million and injectables at $309.55 Million in 2024.

**Q: How does the distribution channel impact the medical morphine market?**
A: Distribution channels include hospital pharmacies, online pharmacies, retail pharmacies, and others, with retail pharmacies valued at $300.0 Million in 2024.

**Q: What applications drive the demand for medical morphine?**
A: Key applications include cancer, arthritis, myocardial infarction, diarrhea, and kidney stones, with cancer alone valued at $350.0 Million in 2024.

**Q: What are the end-user segments for medical morphine?**
A: End-user segments include hospitals and clinics, ambulatory surgical centers, and home care, with hospitals and clinics valued at $309.55 Million in 2024.

**Q: What is the expected growth trend for the medical morphine market in South Korea?**
A: The market appears to be on a growth trajectory, with a projected increase to $1350.0 Million by 2035.

**Q: How do the valuations of different applications compare in the medical morphine market?**
A: In 2024, cancer applications were valued at $350.0 Million, while arthritis applications were valued at $80.0 Million.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-korea-medical-morphine-market-56035*